Reaction: Linaclotide to 1 product

Reaction
Linaclotide
DB08890
    MM-419447
    DBMET00911
    Reaction type
    cleavage
    Direction
    Major circulating metabolite?
    Yes
    Spontaneous?
    No
    Activity
    active
    References
    1. Busby RW, Kessler MM, Bartolini WP, Bryant AP, Hannig G, Higgins CS, Solinga RM, Tobin JV, Wakefield JD, Kurtz CB, Currie MG: Pharmacologic properties, metabolism, and disposition of linaclotide, a novel therapeutic peptide approved for the treatment of irritable bowel syndrome with constipation and chronic idiopathic constipation. J Pharmacol Exp Ther. 2013 Jan;344(1):196-206. doi: 10.1124/jpet.112.199430. Epub 2012 Oct 22. [Article]
    2. FDA Approved Drug Products: LINZESS (linaclotide) Oral Capsules (June 2023) [Link]
    Comments
    Not Available
    Enzymes
    Not Available